HCPLive

When it comes to selecting a biologic for severe asthma, biomarkers are only part of the equation. Payel Gupta, MD, allergist and immunologist at Ease Allergy Clinic and Mount Sinai, breaks down how IgE, FeNO, and blood eosinophil counts inform first-line biologic choice, as well as where the the field still falls short of true precision medicine.
Key clinical takeaways from her conversation with HCPLive:
• About 10% of patients don't respond to the first biologic selected
• If a patient isn't improving within 1–2 months, Gupta typically looks to switch to an agent with a different mechanism of action
• Type 2 comorbidities (atopic dermatitis, EoE, CRSwNP, CSU) can tip the scale toward a biologic approved across multiple indications—a potential "2-for-1" benefit
Read the full Q&A here: https://hubs.li/Q04k_rdD0

New at : Presented in tandem with the TRANSCEND-T2D-1 trial, TRIUMPH-1 has shown retatrutide's groundbreaking weight-loss efficacy in patients with obesity or overweight. Read more about the world's first triple agonist here: https://hubs.li/Q04kpxyx0

New at : Retatrutide, the first GLP-1/GIP/glucagon triple agonist to reach phase 3 testing, has demonstrated substantial results in A1c reduction and weight loss among patients with type 2 diabetes. Read more about the groundbreaking TRANSCEND-T2D-1 trial here: https://hubs.li/Q04kp3__0

Optimizing IL-23–targeted therapy in IBD: when to switch, how to sequence, and what the long-term efficacy and safety data shows.

Join a regional roundtable discussion in Dallas, moderated by Bincy Abraham, MD, MS — a peer-to-peer forum on applying new science in community practice.

Thursday, June 4 · 6:30–8:30 PM CDT · Perry's Steakhouse & Grille, Dallas.
Seats are limited — register now: https://hubs.li/Q04jYnzv0